Literature DB >> 24333653

Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-kappaB-dependent signaling.

Paola Castri, Yang-Ja Lee, Todd Ponzio, Dragan Maric, Maria Spatz, Joliet Bembry, John Hallenbeck.   

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) and its cleavage products regulate cell viability and NF-kappaB activity when expressed in neurons. PARP-1 cleavage generates a 24 kDa (PARP-1(24)) and an 89 kDa fragment (PARP-1(89)). Compared to WT (PARP-1WT), the expression of an uncleavable PARP-1 (PARP-1(UNCL)) or of PARP-1(24) conferred protection from oxygen/glucose deprivation (OGD) or OGD/restoration of oxygen and glucose (ROG) damage in vitro, whereas expression of PARP-1(89) was cytotoxic. Viability experiments were performed in SH-SY5Y, a human neuroblastoma cell line, as well as in rat primary cortical neurons. Following OGD, the higher viability in the presence of PARP-1UNCL or PARP-1(24) was not accompanied with decreased formation of poly(ADP-riboses) or higher NAD levels. PARP-1 is a known cofactor for NF-kappaB, hence we investigated whether PARP-1 cleavage influences the inflammatory response. All PARP-1 constructs mimicked PARP-1WT in regard to induction of NF-kappaB translocation into the nucleus and its increased activation during ischemic challenge. However, expression of PARP-1(89) construct induced significantly higher NF-kB activity than PARP-1WT; and the same was true for NF-kappaB-dependent iNOS promoter binding activity. At a protein level, PARP-1UNCL and PARP-1(24) decreased iNOS (and lower levels of iNOS transcript) and COX-2, and increased Bcl-xL The increased levels of NF-kB and iNOS transcriptional activities, seen with cytotoxic PARP-189, were accompanied by higher protein expression of COX-2 and iNOS (and higher levels of INOS transcript) and lower protein expression of Bcl-xL Taken together, these findings suggest that PARP-1 cleavage products may regulate cellular viability and inflammatory responses in opposing ways during in vitro models of "ischemia".

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24333653      PMCID: PMC4013233          DOI: 10.1016/j.bbamcr.2013.12.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  56 in total

Review 1.  Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.

Authors:  Tiina M Kauppinen
Journal:  Neurochem Int       Date:  2007-01-12       Impact factor: 3.921

2.  Novel systemic markers for patients with Alzheimer disease? - a pilot study.

Authors:  Stefan S Kassner; Gabriel A Bonaterra; Elmar Kaiser; Wulf Hildebrandt; Jürgen Metz; Johannes Schröder; Ralf Kinscherf
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor.

Authors:  Irene Ginis; Rama Jaiswal; Dace Klimanis; Jie Liu; Jose Greenspon; John M Hallenbeck
Journal:  J Cereb Blood Flow Metab       Date:  2002-02       Impact factor: 6.200

4.  Tumor necrosis factor and reactive oxygen species cooperative cytotoxicity is mediated via inhibition of NF-kappaB.

Authors:  I Ginis; J M Hallenbeck; J Liu; M Spatz; R Jaiswal; E Shohami
Journal:  Mol Med       Date:  2000-12       Impact factor: 6.354

5.  Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice.

Authors:  F J Oliver; J Ménissier-de Murcia; C Nacci; P Decker; R Andriantsitohaina; S Muller; G de la Rubia; J C Stoclet; G de Murcia
Journal:  EMBO J       Date:  1999-08-16       Impact factor: 11.598

6.  The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1.

Authors:  W J Chang; R Alvarez-Gonzalez
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

7.  Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion.

Authors:  Aaron M Hamby; Sang Won Suh; Tiina M Kauppinen; Raymond A Swanson
Journal:  Stroke       Date:  2007-02       Impact factor: 7.914

8.  Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis.

Authors:  M E Smulson; D Pang; M Jung; A Dimtchev; S Chasovskikh; A Spoonde; C Simbulan-Rosenthal; D Rosenthal; A Yakovlev; A Dritschilo
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

Review 9.  Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update.

Authors:  C Soldani; A Ivana Scovassi
Journal:  Apoptosis       Date:  2002-08       Impact factor: 4.677

10.  Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis.

Authors:  D D'Amours; F R Sallmann; V M Dixit; G G Poirier
Journal:  J Cell Sci       Date:  2001-10       Impact factor: 5.285

View more
  12 in total

Review 1.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

2.  NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms.

Authors:  Chao Qu; Sheri L Bonar; Cynthia L Hickman-Brecks; Samer Abu-Amer; Matthew D McGeough; Carla A Peña; Lori Broderick; Chang Yang; Susan K Grimston; Jacqueline Kading; Yousef Abu-Amer; Deborah V Novack; Hal M Hoffman; Roberto Civitelli; Gabriel Mbalaviele
Journal:  FASEB J       Date:  2014-12-04       Impact factor: 5.191

Review 3.  Emerging targets for radioprotection and radiosensitization in radiotherapy.

Authors:  Sumit Kumar; Rajnish Kumar Singh; Ramovatar Meena
Journal:  Tumour Biol       Date:  2016-06-19

4.  Noncanonical Cell Death Induction by Reassortant Reovirus.

Authors:  Roxana M Rodríguez Stewart; Vishnu Raghuram; Jameson T L Berry; Gaurav N Joshi; Bernardo A Mainou
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

Review 5.  Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.

Authors:  Peter Makhov; Robert G Uzzo; Alexei V Tulin; Vladimir M Kolenko
Journal:  Urol Oncol       Date:  2020-05-08       Impact factor: 2.954

6.  HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway.

Authors:  Laura Lucarini; Mariaconcetta Durante; Cecilia Lanzi; Alessandro Pini; Giulia Boccalini; Laura Calosi; Flavio Moroni; Emanuela Masini; Guido Mannaioni
Journal:  J Cell Mol Med       Date:  2016-10-04       Impact factor: 5.310

7.  Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib.

Authors:  Kayleigh C Ross; Kevin F Chin; Daehwan Kim; Christopher D Marion; Timothy J Yen; Vikram Bhattacharjee
Journal:  Oncotarget       Date:  2018-01-29

8.  Marine bisindole alkaloid: A potential apoptotic inducer in human cancer cells.

Authors:  Sara Salucci; Sabrina Burattini; Francesca Buontempo; Ester Orsini; Lucia Furiassi; Michele Mari; Simone Lucarini; Alberto M Martelli; Elisabetta Falcieri
Journal:  Eur J Histochem       Date:  2018-04-10       Impact factor: 3.188

Review 9.  Role of APD-Ribosylation in Bone Health and Disease.

Authors:  Chun Wang; Gabriel Mbalaviele
Journal:  Cells       Date:  2019-10-05       Impact factor: 6.600

10.  Roniciclib down-regulates stemness and inhibits cell growth by inducing nucleolar stress in neuroblastoma.

Authors:  Marzia Ognibene; Annalisa Pezzolo
Journal:  Sci Rep       Date:  2020-07-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.